ClinicalTrials.gg
CompletedNCT04400500Updated Dec 11, 2023

Differential Diagnosis and Risk Stratification in Patients With Suspected NSTEACS

An observational study in Non ST Segment Elevation Acute Coronary Syndrome, sponsored by National Research Center for Preventive Medicine. Completed at 1 site in Russian Federation. Per ClinicalTrials.gov, last updated 2023-12-11.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by National Research Center for Preventive Medicine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
140
Sex
All
01

Study summary

To evaluate possibilities of rapid differential diagnosis and risk stratification in patients urgently admitted to the CCU with a suspected acute coronary syndrome without persistent ST-segment elevation (NSTEACS).

Read the detailed description

Single centre prospective non-randomised non-comparative study of patients delivered by ambulance and admitted to the CCU with suspected NSTEACS.

Aims of this study are:

  1. To characterize the contingent of patients admitted to the CCU with suspected NSTEACS.
  2. To evaluate possibilities of fast differential diagnosis and risk stratification in patients admitted to the CCU with suspected NSTEACS using clinical data, ECG, biomarker levels (hsTn, NT-proBNP, hsCPR, cardiac FABP) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.
  3. To evaluate the correlation between clinical data, ECG, biomarker levels (hsTn, NT-proBNP, hsCPR, cardiac FABP) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores with presence and severity of coronary atherosclerosis in patients admitted to the CCU (intensive care unit) with suspected NSTEACS.
02

Conditions studied

  • Non ST Segment Elevation Acute Coronary Syndrome

Browse trials for

Keywords

  • Non ST segment Elevation Acute Coronary Syndrome
  • Diagnosis
  • Prognosis
03

In context

Lead sponsor

National Research Center for Preventive Medicine is the lead sponsor of 18 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients delivered by ambulance and admitted to the CCU with suspected diagnosis "acute coronary syndrome (ACS)".

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Delivered by ambulance to the CCU with suspected diagnosis "acute coronary syndrome (ACS)".
  2. Signed .

Exclusion criteria

Exclusion Criteria:

  1. ACS with persistent ST-segment elevation.
  2. Moribund; extremely severe condition on admission with a potentially unfavourable prognosis (cardiogenic shock, coma, cardiac arrest, an urgent need for mechanical ventilation).
  3. Overt non-cardiac cause of clinical manifestations at the time of admission (bleeding, pulmonary embolism, aortic dissection, stroke).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
140 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Suspected NSTEACS

    Patients urgently admitted to the CCU with suspected NSTEACS

    Diagnostic Test: Approaches to differential diagnosis and risk stratification

Interventions

  • Diagnostic testApproaches to differential diagnosis and risk stratification

    Detailed analysis of clinical course, ECG, biomarkers (hsTn I, CK-MB mass, myoglobin, NT-proBNP, hsCPR, cardiac FABP on admission and after 3 hours; hsTn I, CK-MB mass and myoglobin after 6 hours if needed) as well as HEART, ADAPT, EDACS, T-MACS, GRACE, ACTION and TIMI scores.

06

What researchers measure

Primary outcomes

  1. Clinical outcomes

    Composite of death, (re) infarction, stroke or re-hospitalization

    Time frame: 6 monts

  2. Final diagnosis

    Final diagnosis - the main reason for urgent hospitalization - according to hospital case history

    Time frame: Up to 1 monts

Secondary outcomes

  1. Death

    Death upon discharge and up to 6 months

    Time frame: 6 months.

  2. (re) infarction

    (re) infarction upon discharge and up to 6 months

    Time frame: Up to 1 monts

  3. Stroke

    Stroke upon discharge and up to 6 months

    Time frame: 6 months.

  4. Re-hospitalization

    Recurrent hospital admissions after discharge form the index hospitalization

    Time frame: 6 months.

Other outcomes

  1. Urgent revascularisation

    Revascularisation performed due to sudden clinical deterioration

    Time frame: Up to 1 monts

  2. Other adverse events

    All adverse events/complications not included in clinical outcomes end points.

    Time frame: 6 months.

07

Study locations

1 site
  • Eramishantsev Hospital
    Moscow, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Nov 2023, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2020
First posted
May 22, 2020
StartActual
Mar 1, 2020
Primary completionActual
Nov 30, 2023
CompletionActual
Nov 30, 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04400500
Lead sponsor
National Research Center for Preventive Medicine
Responsible party
Sponsor
First posted
May 22, 2020
Start date
Mar 1, 2020
Primary completion
Nov 30, 2023
Completion
Nov 30, 2023
Last update
Dec 11, 2023

Study contacts

Igor S Yavelov, PhD
principal investigator · National Medical Research Center for Therapy and Preventive Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion